enGene Holdings Inc.

enGene Holdings Inc. Stock Forecast & Price Prediction

Live enGene Holdings Inc. Stock (ENGN) Price
$8.88

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$8.88

P/E Ratio

-1.97

Volume Traded Today

$34,274

Dividend

Dividends not available for ENGN

52 Week High/low

18.40/4.42

enGene Holdings Inc. Market Cap

$376.7M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $ENGN ๐Ÿ›‘

Before you buy ENGN you'll want to see this list of ten stocks that have huge potential. Want to see if ENGN made the cut? Enter your email below

ENGN Summary

The enGene Holdings Inc. (ENGN) share price is expected to increase by 244.26% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered ENGN. Price targets range from $16 at the low end to $40 at the high end. The current analyst consensus for ENGN is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

ENGN Analyst Ratings

About 0 Wall Street analysts have assignedENGN 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect enGene Holdings Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ENGN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

ENGN stock forecast by analyst

These are the latest 20 analyst ratings of ENGN.

Analyst/Firm

Rating

Price Target

Change

Date

Leland Gershell
Oppenheimer

Outperform

$30

Reiterates

Sep 24, 2024
Jeffrey Hung
Morgan Stanley

Overweight

$40

Maintains

Sep 11, 2024
Leland Gershell
Oppenheimer

Outperform

$30

Initiates

Aug 28, 2024
Yanan Zhu
Wells Fargo

Overweight

$30

Initiates

Apr 22, 2024
Manuel Navas
Guggenheim

Buy

$34

Initiates

Apr 15, 2024
Colin Bristow
UBS

Buy

$37

Initiates

Mar 28, 2024
Jeffrey Hung
Morgan Stanley

Overweight

$40

Initiates

Mar 8, 2024
Mani Foroohar
Leerink Partners

Outperform

$31

Initiates

Feb 20, 2024

ENGN Company Information

What They Do: Develops genetic medicines for mucosal tissues.

Business Model: The company operates as a clinical-stage biotechnology firm, generating revenue through the development and potential commercialization of innovative genetic therapies. It focuses on delivering therapeutics specifically to mucosal tissues and other organs, with its lead product targeting bladder cancer patients unresponsive to existing treatments.

Other Information: Founded in 2023 and headquartered in Saint-Laurent, Canada, enGene Holdings Inc. is positioned in the growing biotechnology sector, leveraging its proprietary non-viral immunotherapy platform to address significant unmet medical needs.
ENGN
enGene Holdings Inc. (ENGN)

When did it IPO

2023

Staff Count

31

Country

Canada

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Jason D. Hanson Esq., J.D.

Market Cap

$376.7M

enGene Holdings Inc. (ENGN) Financial Data

In 2023, ENGN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ENGN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$0

Revenue From 2021

$0

0.00 %
From Previous Year

Revenue From 2022

$0

0.00 %
From Previous Year

Revenue From 2023

$0

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -22.1%
  • Return on equity TTM -123.1%
  • Profit Margin 0.0%
  • Book Value Per Share 5.21%
  • Market capitalisation $376.7M
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $0
  • EPS this year (TTM) $-2.79

enGene Holdings Inc. (ENGN) Latest News

News Image

Fri, 25 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - enGene Holdings Inc. is conducting a pivotal study on its lead product, detalimogene voraplasmid, for bladder cancer treatment and has agreed to sell 6,758,311 shares.

Why It Matters - enGene's pivotal study and stock sale indicate progress in its clinical development and potential for funding. This could affect its market valuation and investor sentiment.

News Image

Mon, 21 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - enGene Holdings Inc. appointed Joan Connolly as Chief Executive Officer. The company is conducting a pivotal study on its lead product for high-risk bladder cancer.

Why It Matters - The appointment of a new Chief Executive Officer can signal strategic shifts and leadership changes that may impact enGene's direction and stock performance, crucial for investors tracking the company's progress.

News Image

Tue, 22 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - enGene Holdings Inc. announced the grant of an inducement equity award as it continues a pivotal study for its lead product, detalimogene voraplasmid, targeting high-risk NMIBC patients.

Why It Matters - enGene's pivotal study results could impact stock performance and market perception, especially in biotech, as success in treating high-risk cancer may lead to increased demand and valuation.

News Image

Tue, 01 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - enGene Holdings Inc. reported the grant of inducement equity awards as it continues a pivotal study on its lead product, detalimogene voraplasmid, for high-risk bladder cancer.

Why It Matters - The grant of inducement equity awards suggests management's confidence in the company's prospects, potentially influencing investor sentiment and stock performance.

News Image

Thu, 26 Sep 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - enGene Holdings Inc. announced preliminary data from its pivotal study on detalimogene voraplasmid for high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Why It Matters - Preliminary data on enGene's lead product for bladder cancer may signal progress in a pivotal study, potentially influencing stock performance and investor sentiment in biotech.

News Image

Tue, 10 Sep 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - enGene Holdings Inc. reported its Q3 financial results and is conducting a pivotal study on its lead product, detalimogene voraplasmid, for high-risk non-muscle invasive bladder cancer.

Why It Matters - enGene's pivotal study for a cancer treatment positions it for potential market success, impacting stock performance and investor sentiment based on clinical outcomes and financial health.

...

ENGN Frequently asked questions

The highest forecasted price for ENGN is $40 from Jeffrey Hung at Morgan Stanley.

The lowest forecasted price for ENGN is $16 from from

The ENGN analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.